je.st
news
Tag: hcv
Premarket Biotech Digest: Anavex's Results, Gilead's HCV Sales, Sanofi's Strategic Roadmap
2015-11-09 20:25:41| Biotech - Topix.net
Click this link to find out how much you can save.) Anavex is down 8% premarket after a large drop on Friday, just before the Nov 7 results from 32 patients in its phase 2a trial part A. I plan to do a thorough study of this tomorrow, but meanwhile, here are a few quick thoughts for those who are undecided about whether to sell or hold. . First, if you want to follow someone's advice, take it in its entirety, don't do it piecemeal.
Tags: results
sales
strategic
digest
Premarket Biotech Digest: Hillary's Tweet, Arrowhead Investor Day, Gilead's HCV Success
2015-09-22 17:02:28| Biotech - Topix.net
A left-leaning tweet from Democratic Presidential candidate Hillary Clinton sent biotech stocks spiraling downwards yesterday, providing an opportunity for us poor investors to buy a few good price-gouging stocks at the dip. Hillary promises more biotech attack today, so watch out for further opportunities.
Tags: day
success
investor
digest
Merck's potential HCV drug gets special FDA designation
2015-04-08 14:57:08| Biotech - Topix.net
Merck & Co. said Wednesday that the Food and Drug Administration granted the pharmaceutical company's developing hepatitis C treatment two special designations.
Tags: special
potential
drug
designation
Grazoprevir/Elbasvir, Mercks Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
2015-04-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Joe Romanelli, 908-740-1879Justin Holko, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
types
Abbvie Projects $3B Sales For HCV Cocktail, But Shares Fall 3%
2015-02-02 19:46:47| Biotech - Topix.net
Abbvie reported solid Q4 earnings last week, despite one-time expenses for fees related to backing out of acquiring Shire Plc. Management did nothing to assuage investors that its HCV regimen was on pace to achieve its $2 billion 2015 revenue target.
Tags: sales
fall
projects
shares